The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 3, 2006, Pages 3081-3095

  Smith Jr , Gerald N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cartilage; Collagenase; Matrix Metalloproteinases; Osteoarthritis; Review

Indexed keywords

EID: 33744496575     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2034     Document Type: Review

References (121)

1. Broom, N., M. H. Chen & A. Hardy: A degeneration-based hypothesis for interpreting fibrillar changes in the osteoarthritic cartilage matrix. J Anat, 199, 683-98 (2001)
2. Eyre, D. R.: Collagens and cartilage matrix homeostasis. Clin Orthop Rel Res, 427, S118-22 (2004)
3. Mayne, R.: Cartilage collagens. What is their function, and are they involved in articular disease? Arthritis Rheum, 32, 241-6 (1989)
4. Burgeson, R. E.: New collagens, new concepts. Annu Rev Cell Biol, 4, 551-77 (1988)
5. Morris, N. P. & H. P. Bachinger: Type XI collagen is a heterotrimer with the composition (1 alpha, 2 alpha, 3 alpha) retaining non-triple-helical domains. J Biol Chem, 262, 11345-50 (1987)
6. Vaughan, L., M. Mendler, S. Huber, P. Bruckner, K. H. Winterhalter, M. I. Irwin & R. Mayne: D-periodic distribution of collagen type IX along cartilage fibrils. J Cell Biol, 106, 991-7 (1988)
7. Vasios, G., I. Nishimura, H. Konomi, M. van der Rest, Y. Ninomiya & B. R. Olsen: Cartilage type IX collagen-proteoglycan contains a large amino-terminal globular domain encoded by multiple exons. J Biol Chem, 263, 2324-9 (1988)
8. Eyre, D. R., J. J. Wu, R. J. Fernandes, T. A. Pietka & M. A. Weis: Recent developments in cartilage research: matrix biology of the collagen II/IX/XI heterofibril network. Biochem Soc Trans, 30, 893-9 (2002)
9. Eyre, D. R., T. Pietka, M. A. Weis & J.-J. Wu: Covalent cross-linking of the NC1 domain of collagen type IX to collagen type II in cartilage. J Biol Chem, 279, 2568-74 (2004)
10. Miles, C. A., L. Knott, I. G. Sumner & A. J. Bailey: Differences between the thermal stabilities of the three triple-helical domains of type IX collagen. J Mol Biol, 277, 135-44 (1998)
11. Konomi, H., J. M. Seyer, Y. Ninomiya & B. R. Olsen: Peptide-specific antibodies identify the alpha 2 chain as the proteoglycan subunit of type IX collagen. J Biol Chem, 261, 6742-6 (1986)
12. Cremer, M. A., E. F. Rosloniec & A. H. Kang: The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med, 76, 275-88 (1998)
13. Mendler, M., S. G. Eich-Bender, L. Vaughan, K. H. Winterhalter & P. Bruckner: Cartilage contains mixed fibrils of collagen types II, IX, and XI. J Cell Biol, 108, 191-7 (1989)
14. McDevitt, C. A., J. A. Pahl, S. Ayad, R. R. Miller, M. Uratsuji & J. T. Andrish: Experimental osteoarthritic articular cartilage is enriched in guanidine soluble type VI collagen. Biochem Biophys Res Comm, 157, 250-5 (1988)
15. Hambach, L., D. Neureiter, G. Zeiler, T. Kirchner & T. Aigner: Severe disturbance of the distribution and expression of type VI collagen chains in osteoarthritic articular cartilage. Arthritis Rheum, 41, 986-96 (1998)
16. Kielty, C. M., M. Lees, C. A. Shuttleworth & D. Woolley: Catabolism of intact type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem Biophys Res Comm, 191, 1230-6 (1993)
17. Visse, R. & H. Nagase: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res, 92, 827-39 (2003)
18. Shlopov, B. V., W. R. Lie, C. L. Mainardi, A. A. Cole, S. Chubinskaya & K. A. Hasty: Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum, 40, 2065-74 (1997)
19. Bau, B., P. M. Gebhard, J. Haag, T. Knorr, E. Bartnik & T. Aigner: Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum, 46, 2648-57 (2002)
20. Kevorkian, L., D. A. Young, C. Darrah, S. T. Donell, L. Shepstone, S. Porter, S. M. Brockbank, D. R. Edwards, A. E. Parker & I. M. Clark: Expression profiling of metalloproteinases and their inhibitors in cartilage. [see comment]. Arthritis Rheum, 50, 131-41 (2004)
21. Bluteau, G., T. Conrozier, P. Mathieu, E. Vignon, D. Herbage & F. Mallein-Gerin: Matrix metalloproteinase-1, - 3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. Biochim Biophys Acta, 1526, 147-58 (2001)
22. Ohuchi, E., K. Imai, Y. Fujii, H. Sato, M. Seiki & Y. Okada: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem, 272, 2446-51 (1997)
23. Brinckerhoff, C. E. & L. M. Matrisian: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol, 3, 207-14 (2002)
24. Stetler-Stevenson, W. G.: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev, 9, 289-303 (1990)
25. Senior, R. M., G. L. Griffin, C. J. Fliszar, S. D. Shapiro, G. I. Goldberg & H. G. Welgus: Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem, 266, 7870-5 (1991)
26. Stuart, P. M., F. Pan, X. Yin, Z. Haskova, S. Plambeck & T. A. Ferguson: Effect of metalloprotease inhibitors on corneal allograft survival. Invest Ophthalmol Vis Sci, 45, 1169-73 (2004)
27. Aimes, R. T. & J. P. Quigley: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments. J Biol Chem, 270, 5872-6 (1995)
28. Konttinen, Y. T., A. Ceponis, M. Takagi, M. Ainola, T. Sorsa, M. Sutinen, T. Salo, J. Ma, S. Santavirta & M. Seiki: New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol, 17, 585-601 (1998)
29. Itoh, Y., M. Kajita, H. Kinoh, H. Mori, A. Okada & M. Seiki: Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. J Biol Chem, 274, 34260-6 (1999)
30. Rozanov, D. V., E. I. Deryugina, B. I. Ratnikov, E. Z. Monosov, G. N. Marchenko, J. P. Quigley & A. Y. Strongin: Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys (574), the active site Glu (240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. J Biol Chem, 276, 25705-14 (2001)
31. Mix, K. S., J. A. Mengshol, U. Benbow, M. P. Vincenti, M. B. Sporn & C. E. Brinckerhoff: A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum, 44, 1096-104 (2001)
32. Westermarck, J. & V. M. Kahari: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 13, 781-92 (1999)
33. Curran, S. & G. I. Murray: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer, 36, 1621-30 (2000)
34. Schroen, D. J. & C. E. Brinckerhoff: Inhibition of rabbit collagenase (matrix metalloproteinase-1; MMP-1) transcription by retinoid receptors: evidence for binding of RARs/RXRs to the -77 AP-1 site through interactions with c-Jun. J Cell Physiol, 169, 320-32 (1996)
35. Jonat, C., B. Stein, H. Ponta, P. Herrlich & H. J. Rahmsdorf: Positive and negative regulation of collagenase gene expression. Matrix Suppl, 1, 145-55 (1992)
36. Tardif, G., P. Reboul, M. Dupuis, C. Geng, N. Duval, J. P. Pelletier & J. Martel-Pelletier: Transforming growth factor-beta induced collagenase-3 production in human osteoarthritic chondrocytes is triggered by Smad proteins: cooperation between activator protein-1 and PEA-3 binding sites. J Rheum, 28, 1631-9 (2001)
37. Shlopov, B. V., G. N. Smith, Jr., A. A. Cole & K. A. Hasty: Differential patterns of response to doxycycline and transforming growth factor beta1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum, 42, 719-27 (1999)
38. Buisson-Legendre, N., S. Smith, L. March & C. Jackson: Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis Rheum, 50, 2151-6 (2004)
39. Fujisawa, T., T. Hattori, K. Takahashi, T. Kuboki, A. Yamashita & M. Takigawa: Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J Biochem, 125, 966-75 (1999)
40. Honda, K., S. Ohno, K. Tanimoto, C. Ijuin, N. Tanaka, T. Doi, Y. Kato & K. Tanne: The effects of high magnitude cyclic tensile load on cartilage matrix metabolism in cultured chondrocytes. Eur J Cell Biol, 79, 601-9 (2000)
41. Sun, H. B. & H. Yokota: Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells. Matrix Biol, 21, 263-70 (2002)
42. Benbow, U. & C. E. Brinckerhoff: The AP-1 site and MMP gene regulation: what is all flie fuss about? Matrix Biol, 15, 519-26 (1997)
43. Vincenti, M. P.: The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Meth Molec Biol, 151, 121-48 (2001)
44. Mengshol, J. A., M. P. Vincenti, C. I. Coon, A. Barchowsky & C. E. Brinckerhoff: Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum, 43, 801-11 (2000)
45. Mengshol, J. A., K. S. Mix & C. E. Brinckerhoff: Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum, 46, 13-20 (2002)
46. Lohi, J., K. Lehti, H. Valtanen, W. C. Parks & J. Keski-Oja: Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene, 242, 75-86 (2000)
47. Smith, G. N., Jr., K. A. Hasty, L. P. Yu, Jr., K. S. Lamberson, E. A. Mickler & K. D. Brandt: Cleavage of type XI collagen fibers by gelatinase and by extracts of osteoarthritic canine cartilage. Matrix, 11, 36-42 (1991)
48. Baker, A. H., D. R. Edwards & G. Murphy: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci, 115, 3719-27 (2002)
49. Takahashi, C., Z. Sheng, T. P. Horan, H. Kitayama, M. Maki, K. Hitomi, Y. Kitaura, S. Takai, R. M. Sasahara, A. Horimoto, Y. Ikawa, B. J. Ratzkin, T. Arakawa & M. Noda: Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A, 95, 13221-6 (1998)
50. van Lent, P. L., P. N. Span, A. W. Sloetjes, T. R. Radstake, A. W. van Lieshout, J. J. Heuvel, C. G. Sweep & W. B. van den Berg: Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis. Ann Rheumatic Dis, 64, 368-74 (2005)
51. Hausser, H. J., R. Decking & R. E. Brenner: Testican-1, an inhibitor of pro-MMP-2 activation, is expressed in cartilage. Osteoarthritis Cartilage, 12, 870-7 (2004)
52. Bonnet, F., J. P. Perin, P. Maillet, P. Jolles & P. M. Alliel: Characterization of a human seminal plasma glycosaminoglycan-bearing polypeptide. Biochem J, 288, 565-9 (1992)
53. Nakada, M., A. Yamada, T. Takino, H. Miyamori, T. Takahashi, J. Yamashita & H. Sato: Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res, 61, 8896-902 (2001)
54. Van Wart, H. E. & H. Birkedal-Hansen: The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA, 87, 5578-82 (1990)
55. Altman, R. D., D. D. Dean, O. E. Muniz & D. S. Howell: Prophylactic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester. Arthritis Rheum, 32, 759-66 (1989)
56. Goldberg, G. I., S. M. Frisch, C. He, S. M. Wilhelm, R. Reich & I. E. Collier: Secreted proteases. Regulation of their activity and their possible role in metastasis. Ann N Y Acad Sci, 580, 375-84 (1990)
57. Murphy, G., R. Ward, J. Gavrilovic & S. Atkinson: Physiological mechanisms for metalloproteinase activation. Matrix Suppl, 1, 224-30 (1992)
58. Yu, A. E., R. E. Hewitt, D. E. Kleiner & W. G. Stetler-Stevenson: Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem Cell Biol, 74, 823-31 (1996)
59. Knauper, V., S. M. Wilhelm, P. K. Seperack, Y. A. DeClerck, K. E. Iangley, A. Osthues & H. Tschesche: Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J, 295, 581-6 (1993)
60. Cowell, S., V. Knauper, M. L. Stewart, M. P. D'Ortho, H. Stanton, R. M. Hembry, C. Lopez-Otin, J. J. Reynolds & G. Murphy: Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J, 331, 453-8 (1998)
61. Rajagopalan, S., X. P. Meng, S. Ramasamy, D. G. Harrison & Z. S. Galis: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest, 98, 2572-9 (1996)
62. Ramamurthy, N. S., A. T. Vernillo, R. A. Greenwald, H. M. Lee, T. Sorsa, L. M. Golub & B. R. Rifkin: Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Min Res, 8, 1247-53 (1993)
63. Milner, J. M, S. F. Elliott & T. E. Cawston: Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum, 44, 2084-96 (2001)
64. Kusano, K., C. Miyaura, M. Inada, T. Tamura, A. Ito, H. Nagase, K. Kamoi & T. Suda: Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology, 139, 1338-45 (1998)
65. Nguyen, M., J. Arkell & C. J. Jackson: Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MT1 matrix metalloproteinase. Lab Invest, 79, 467-75 (1999)
66. Murphy, G., H. Stanton, S. Cowell, G. Butler, V. Knauper, S. Atkinson & J. Gavrilovic: Mechanisms for pro matrix metalloproteinase activation. APMIS, 107, 38-44 (1999)
67. Murphy, G., V. Knauper, S. Cowell, R. Hembry, H. Stanton, G. Butler, J. Freije, A. M. Pendas & C. Lopez-Otin: Evaluation of some newer matrix metalloproteinases. Ann NY Acad Sci, 878, 25-39 (1999)
68. Mitchell, P. G., H. A. Magna, L. M. Reeves, L. L. Lopresti-Morrow, S. A. Yocum, P. J. Rosner, K. F. Geoghegan & J. E. Hambor: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest, 97, 761-8 (1996)
69. Knauper, V., C. Lopez-Otin, B. Smith, G. Knight & G. Murphy: Biochemical characterization of human collagenase-3. J Biol Chem, 271, 1544-50 (1996)
70. McGuire, M. B., G. Murphy, J. J. Reynolds & R. G. Russell: Production of collagenase and inhibitor (TIMP) by normal, rheumatoid and osteoarthritic synovium in vitro: effects of hydrocortisone and indomethacin. Clin Sci, 61, 703-10 (1981)
71. Pourmotabbed, T., T. L. Solomon, K. A. Hasty & C. L. Mainardi: Characteristics of 92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells: structure, expression of cDNA in E. coli and enzymic properties. Biochim Biophysic Acta, 1204, 97-107 (1994)
72. Mainardi, C. L., M. S. Hibbs, K. A. Hasty & J. M. Seyer: Purification of a type V collagen degrading metalloproteinase from rabbit alveolar macrophages. Coll Rel Res, 4, 479-92 (1984)
73. Yu, L. P., Jr., G. N. Smith, Jr., K. D. Brandt & W. Capello: Type XI collagen-degrading activity in human osteoarthritic cartilage. Arthritis Rheum, 33, 1626-33 (1990)
74. Okada, Y., H. Konomi, T. Yada, K. Kimata & H. Nagase: Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells. FEBS Letters, 244, 473-6 (1989)
75. Douglas, S. P., J. M. Jenkins & K. E. Kadler: Collagen IX: evidence for a structural association between NC4 domains in cartilage and a novel cleavage site in the alpha 1 (IX) chain. Matrix Biol, 16, 497-505 (1998)
76. Ehrlich, M. G., H. J. Mankin, H. Jones, R. Wright, C. Crispen & G. Vigliani: Collagenase and collagenase inhibitors in osteoarthritic and normal cartilage. J Clin Invest, 59, 226-33 (1977)
77. Ehrlich, M. G., P. A. Houle, G. Vigliani & H. J. Mankin: Correlation between articular cartilage collagenase activity and osteoarthritis. Arthritis Rheum, 21, 761-6 (1978)
78. Pelletier, J. P. & J. Martel-Pelletier: In vitro effects of tiaprofenic acid, sodium salicylate and hydrocortisone on human osteoarthritic cartilage degradation and synovial collagenase synthesis. Drugs, 35 Suppl 1, 42-5 (1988)
79. Pelletier, J. P. & J. Martel-Pelletier: Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs, 46 Suppl 1, 34-9 (1993)
80. Freije, J. M., I. Diez-Itza, M. Balbin, L. M. Sanchez, R. Blasco, J. Tolivia & C. Lopez-Otin: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem, 269, 16766-73 (1994)
81. Reboul, P., J. P. Pelletier, G. Tardif, J. M. Cloutier & J. Martel-Pelletier: The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest, 97, 2011-9 (1996)
82. Flannelly, J., M. G. Chambers, J. Dudhia, R. M. Hembry, G. Murphy, R. M. Mason & M. T. Bayliss: Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis. Osteoarthritis Cartilage, 10, 722-33 (2002)
83. Yu, L. P., Jr., G. N. Smith, Jr., K. D. Brandt, S. L. Myers, B. L. O'Connor & D. A. Brandt: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. [see comment]. Arthritis Rheum, 35, 1150-9 (1992)
84. Pelletier, J. P., J. Martel-Pelletier, D. S. Howell, L. Ghandur-Mnaymneh, J. E. Enis & J. F. Woessner, Jr.: Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum, 26, 63-8 (1983)
85. Pelletier, J. P., J. Martel-Pelletier, R. D. Altman, L. Ghandur-Mnaymneh, D. S. Howell & J. F. Woessner, Jr.: Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum, 26, 866-74 (1983)
86. Nguyen, Q., J. S. Mort & P. J. Roughley: Preferential mRNA expression of prostromelysin relative to procollagenase and in situ localization in human articular cartilage. J Clin Invest, 89, 1189-97 (1992)
87. Bandara, G., C. W. Lin, H. I. Georgescu, D. Mendelow & C. H. Evans: Chondrocyte activation by interleukin-1:6 analysis of the synergistic properties of fibroblast growth factor and phorbol myristate acetate. Arch Biochem Biophys, 274, 539-47 (1989)
88. Hasty, K. A., T. F. Pourmotabbed, G. I. Goldberg, J. P. Thompson, D. G. Spinella, R. M. Stevens & C. L. Mainardi: Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem, 265, 11421-4 (1990)
89. Chubinskaya, S., K. Huch, K. Mikecz, G. Cs-Szabo, K. A. Hasty, K. E. Kuettner & A. A. Cole: Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. Lab Invest, 74, 232-40 (1996)
90. Imai, K., S. Ohta, T. Matsumoto, N. Fujimoto, H. Sato, M. Seiki & Y. Okada: Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Am J Pathol, 151, 245-56 (1997)
91. Kumar, S., J. R. Connor, R. A. Dodds, W. Halsey, M. Van Horn, J. Mao, G. Sathe, P. Mui, P. Agarwal, A. M. Badger, J. C. Lee, M. Gowen & M. W. Lark: Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries. Osteoarthritis Cartilage, 9, 641-53 (2001)
92. Billinghurst, R. C., L. Dahlberg, M. Ionescu, A. Reiner, R. Bourne, C. Rorabeck, P. Mitchell, J. Hambor, O. Diekmann, H. Tschesche, J. Chen, H. Van Wart & A. R. Poole: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest, 99, 1534-45 (1997)
93. Otterness, I. G., J. T. Downs, C. Lane, M. L. Bliven, H. Stukenbrok, D. N. Scampoli, A. J. Milici & P. S. Mezes: Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biol, 18, 331-41 (1999)
94. Dahlberg, L., R. C. Billinghurst, P. Manner, F. Nelson, G. Webb, M. Ionescu, A. Reiner, M. Tanzer, D. Zukor, J. Chen, H. E. van Wart & A. R. Poole: Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum, 43, 673-82 (2000)
95. Hollander, A. P., I. Pidoux, A. Reiner, C. Rorabeck, R. Bourne & A. R. Poole: Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest, 96, 2859-69 (1995)
96. Billinghurst, R. C., F. Mwale, A. Hollander, M. Ionescu & A. R. Poole: Immunoassays for collagens in chondrocyte and cartilage expiant cultures. Meth Molec Med, 100, 251-74 (2004)
97. Hollander, A. P., T. F. Heathfield, C. Webber, Y. Iwata, R. Bourne, C. Rorabeck & A. R. Poole: Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest, 93, 1722-32 (1994)
98. Huebner, J. L., I. G. Otterness, E. M. Freund, B. Caterson & V. B. Kraus: Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. [see comment]. Arthritis Rheum, 41, 877-90 (1998)
99. Chu, Q., M. Lopez, K. Hayashi, M. Ionescu, R. C. Billinghurst, K. A. Johnson, A. R. Poole & M. D. Markel: Elevation of a collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage, 10, 662-9 (2002)
100. Freemont, A. J., R. J. Byers, Y. O. Taiwo & J. A. Hoyland: In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage. Ann Rheum Dis, 58, 357-65 (1999)
101. Neuhold, L. A., L. Killar, W. Zhao, M. L. Sung, L. Warner, J. Kulik, J. Turner, W. Wu, C. Billinghurst, T. Meijers, A. R. Poole, P. Babij & L. J. DeGennaro: Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. [see comment]. J Clin Invest, 107, 35-44 (2001)
102. Clements, K. M., J. S. Price, M. G. Chambers, D. M. Visco, A. R. Poole & R. M. Mason: Gene deletion of either interleukin-1beta, interleukin-1 beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. [see comment]. Arthritis Rheum, 48, 3452-63 (2003)
103. Rasmussen, H. S. & P. P. McCann: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther, 75, 69-75 (1997)
104. Renkiewicz, R., L. Qiu, C. Lesch, X. Sun, R. Devalaraja, T. Cody, E. Kaldjian, H. Welgus & V. Baragi: Broad- spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum, 48, 1742-9 (2003)
105. Brewster, M., E. J. Lewis, K. L. Wilson, A. K. Greenham & K. M. Bottomley: Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum, 41, 1639-44 (1998)
106. Janusz, M. J., A. M. Bendele, K. K. Brown, Y. O. Taiwo, L. Hsieh & S. A. Heitmeyer: Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor. [erratum appears in Osteoarthritis Cartilage 2002 Nov; 10 (1):905]. Osteoarthritis Cartilage, 10, 785-91 (2002)
107. Close, D. R.: Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis, 60 Suppl 3, iii62-7 (2001)
108. Brandt, K. D., S. A. Mazzuca, B. P. Katz, K. A. Lane, K. A. Buckwalter, D. E. Yocum, F. Wolfe, T. J. Schnitzer, L. W. Moreland, S. Manzi, J. D. Bradley, L. Sharma, C. V. Oddis, S. T. Hugenberg & L. W. Heck: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. [see comment]. Arthritis Rheum, 52, 2015-25 (2005)
109. Ratcliffe, A., W. Azzo, F. Saed-Nejad, N. Lane, M. P. Rosenwasser & V. C. Mow: In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage. J Orthop Res, 11, 163-71 (1993)
110. Fernandes, J. C., J. P. Caron, J. Martel-Pelletier, D. Jovanovic, F. Mineau, G. Tardif, I. G. Otterness & J. P. Pelletier: Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis Rheum, 40, 284-94 (1997)
111. DiBattista, J. A., J. Martel-Pelletier, T. Antakly, G. Tardif, J. M. Cloutier & J. P. Pelletier: Reduced expression of glucocorticoid receptor levels in human osteoarthritic chondrocytes. Role in the suppression of metalloprotease synthesis. J Clin Endocrinol Metab, 76, 1128-34 (1993)
112. Balblanc, J. C., E. Vignon, P. Mathieu, P. Broquet, T. Conrozier & M. Richard: [Cytokines, prostaglandin E2, phospholipase A and metalloproteases in synovial fluid in osteoarthritis]. Rev Rhum Mal Osteoartic, 58, 343-7 (1991)
113. Vignon, E., P. Mathieu, P. Broquet, P. Louisot & M. Richard: Cartilage degradative enzymes in human osteoarthritis: effect of a nonsteroidal antiinflammatory drug administered orally. Seminars in Arthritis Rheum, 19, 26-9 (1990)
114. Pelletier, J. P., C. Boileau, J. Brunet, M. Boily, D. Lajeunesse, P. Reboul, S. Laufer & J. Martel-Pelletier: The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone, 34, 527-38 (2004)
115. Badger, A. M., J. N. Bradbeer, B. Votta, J. C. Lee, J. L. Adams & D. E. Griswold: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther, 279, 1453-61 (1996)
116. Pelletier, J. P., V. Lascau-Coman, D. Jovanovic, J. C. Fernandes, P. Manning, J. R. Connor, M. G. Currie & J. Martel- Pelletier: Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheum, 26, 2002-14 (1999)
117. Pelletier, J. P., D. Jovanovic, J. C. Fernandes, P. Manning, J. R. Connor, M. G. Currie, J. A. Di Battista & J. Martel- Pelletier: Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum, 41, 1275-86 (1998)
118. Campbell, I. K., S. Gerondakis, K. O'Donnell & I. P. Wicks: Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest, 105, 1799-806 (2000)
119. Smith, G. N., Jr., L. P. Yu, Jr., K. D. Brandt & W. N. Capello: Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheum, 25, 532-5 (1998)
120. Shlopov, B. V., J. M. Stuart, M. L. Gumanovskaya & K. A. Hasty: Regulation of cartilage collagenase by doxycycline. J Rheum, 28, 835-42 (2001)
121. Nagase, H. & M. Kashiwagi: Aggrecanases and cartilage matrix degradation. Arthritis Res Ther, 5, 94-103 (2003)